This article is more than 5 years old. Information may no longer be current.
Medical Center appoints director of thoracic oncology immunotherapeutics
Click Here to Manage Email Alerts
Naiyer A. Rizvi, MD, has been named director of thoracic oncology and immunotherapeutics in medical oncology at NewYork-Presbyterian/Columbia University Medical Center.
Rizvi, a medical oncologist, previously served as an attending physician at Memorial Sloan Kettering Cancer Center, where he led research in thoracic immunotherapy. He also served as an associate professor of medicine at Weill Cornell Medical College.
Naiyer A. Rizvi
Rizvi has led key trials using immune checkpoint blockade therapy, and he intends to continue his research to develop new immunotherapy agents and combinations for cancer treatment.
“Dr. Rizvi’s research of antibodies that can reinvigorate T cells to recognize lung cancer cells as foreign and destroy the cancer cells has been a major development in thoracic oncology,” Gary Schwartz, MD, professor of medicine at Columbia University College of Physicians and Surgeons and chief of the division of hematology/oncology at NewYork-Presbyterian/Columbia, said in a press release. “We are excited to bring him on board to lead our program in thoracic oncology and to integrate his years of experience and breadth of knowledge in treating patients with all types of cancer that could respond to immunotherapies.”